Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in FGFR2-fusion positive biliary cancer
NCT02265341Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in biliary tract cancer (BTC), sponsored by Mayo Clinic. Started Dec 2014; status: completed.
02
Drugs
ponatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02265341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265341.